Bioelectronics Corp (BIEL): RecoveryRX

Play Episode

9min

Proactive - Interviews for investors

How Beforepay’s AI model drives strong returns

Beforepay Group Ltd Finance Manager Shreya Prakash talked with Proactive about the company’s dual focus on domestic consumer lending and enterprise software through its Carrington Labs division. She explained that Beforepay’s core product—a pay advance offering—provides short-term loans with a fixed 5% fee and no hidden costs, aiming to support Australians with transparent and ethical lending. Prakash said, “The most common reason people borrow from us is not because they want to go for a vacation... but to tide them over that short-term cash flow pinch.” She highlighted that this flagship product, launched in 2020, remains central to the business and differentiates itself through its ethical model and efficient cost structure. Carrington Labs, the company’s AI and analytics arm, is productising the risk models that power Beforepay and expanding operations in the US. Prakash noted that the company is writing around 40,000 loans with just 50 staff, underlining a strong operational efficiency. Billy Cheung, also from the finance team, added that Beforepay became profitable in the first half of FY23. He reported revenue approaching A$20 million and net profit of A$2.8 million in H1 FY25. Notably, the company reduced net defaults from around 3% to just 1.1%, attributing this to improved credit risk models. Cheung also mentioned growth in personal loan offerings and continued investment into Carrington Labs. While Beforepay’s main focus remains on the Australian market, the company is actively expanding Carrington Labs internationally, particularly in the US. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Beforepay #ASXB4P #FintechAustralia #EthicalLending #PayAdvance #CarringtonLabs #AIinFinance #ConsumerLending #PersonalFinance #FinancialWellbeing #InvestorUpdate #ProactiveInvestors #FinanceInterview #ASXStocks #FintechNews

Proactive - Interviews for investors

DP Poland CEO Nils Gornall on Pizzeria 105 acquisition strategy

DP Poland PLC (AIM:DPP) CEO Nils Gornall talked with Proactive about the company’s acquisition of Pizzeria 105 in Poland for £8.5 million — a key step in its strategy to transition towards a franchise-led business model. Gornall explained that DP Poland is the master franchisee of Domino’s Pizza in both Poland and Croatia, and this latest acquisition boosts the company’s franchised store percentage from just 8% three years ago to over 50% today. “The best Domino’s businesses around the world are franchisee-led. That's where we need to be,” he said. Pizzeria 105 is the fourth-largest pizza chain in Poland, with 90 franchised stores. Gornall emphasised how this acquisition aligns with DP Poland’s strategy, highlighting the opportunity to bring Domino’s global brand power and systems to a well-established local operator. “We have the tools to help the franchisees really take it to that next level,” he said. Looking ahead, Gornall noted the goal of rebranding all Pizzeria 105 stores to Domino’s within 24 months, with a target of reaching 200 fully branded Domino’s outlets by late 2026 or early 2027. The transaction also adds more than 80 franchise business owners to DP Poland’s ecosystem and supports a shift toward selling down corporate-owned stores. He said the key focus now is rebranding and driving sales performance with Domino’s marketing and operational capabilities. The long-term ambition is to move from 50% to 90% franchise ownership. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #DPoland #DominosPizza #FranchiseGrowth #PizzaMarket #PolandBusiness #DominosPoland #NilsGornall #FoodIndustry #FranchiseStrategy #Pizzeria105 #CompanyAcquisition #InvestingInPoland #FastFoodBusiness

Proactive - Interviews for investors

Hillcrest launches ZVS technology evaluation with global Tier 1 automotive supplier

Hillcrest Energy Technologies CEO Don Currie joined Steve Darling from Proactive to announce the launch of a technology evaluation project with a global Tier 1 automotive supplier. The project’s initial phase will assess the potential benefits of Hillcrest’s Zero Voltage Switching (ZVS) technology in next-generation inverter applications for electric vehicles. If this phase is successful and both parties agree to proceed, subsequent phases will focus on the integration and validation of ZVS technology within the supplier’s inverter platform. Currie explained that Tier 1 automotive suppliers provide fully assembled components and systems to major automakers. This particular supplier, consistently ranked among the top 15 largest by revenue, is a global leader specializing in critical EV components like inverters. With a strong presence in the industry, the supplier plays a crucial role in advancing electric vehicle technology for manufacturers worldwide. The evaluation phase will involve a series of technical assessments aimed at eliminating switching losses and improving electromagnetic compatibility (EMC) performance. The supplier will analyze efficiency, performance, and potential advantages of Hillcrest’s ZVS technology within its inverter architecture. The findings from this evaluation will determine potential next steps for further collaboration and integration. This project represents a key opportunity for Hillcrest to demonstrate the value of its ZVS technology, with the shared objective of enhancing EV inverter performance and delivering significant benefits to automotive customers. #proactiveinvestors #hillcrestenergytechnologiesltd #cse #heat #ptcqb #hlrtf

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	33
Posts	5349
Boards Moderated	0
Alias Born	11/05/2018

Volume:	1,016,313
Day Range:	0.0001 - 0.00025
Bid:	0.0002
Ask:	0.0003
Last Trade Time:	3:23:46 PM EDT
Total Trades:	8

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BIEL Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free